Niagen Bioscience, Inc.
NAGE
$10.04
$0.010.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.09% | 4.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.09% | 4.66% | |||
| Cost of Revenue | -2.32% | 2.03% | |||
| Gross Profit | 4.63% | 6.23% | |||
| SG&A Expenses | 16.34% | 36.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.65% | 16.78% | |||
| Operating Income | -33.26% | -32.89% | |||
| Income Before Tax | -28.56% | -30.10% | |||
| Income Tax Expenses | -23.81% | -44.92% | |||
| Earnings from Continuing Operations | -28.72% | -29.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.72% | -29.47% | |||
| EBIT | -33.26% | -32.89% | |||
| EBITDA | -31.93% | -31.96% | |||
| EPS Basic | -30.11% | -30.23% | |||
| Normalized Basic EPS | -29.76% | -30.92% | |||
| EPS Diluted | -33.33% | -30.56% | |||
| Normalized Diluted EPS | -31.04% | -31.41% | |||
| Average Basic Shares Outstanding | 1.85% | 1.12% | |||
| Average Diluted Shares Outstanding | 3.62% | 1.90% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||